ライフサイエンスコーパス: urothelial carcinoma

1 with non-small-cell lung cancer, and 24 with urothelial carcinoma).

2 patients with locally advanced or metastatic urothelial carcinoma.

3 igation of nivolumab monotherapy in advanced urothelial carcinoma.

4 patients with locally advanced or metastatic urothelial carcinoma.

5 patients with locally advanced or metastatic urothelial carcinoma.

6 response to this class of agents in advanced urothelial carcinoma.

7 ed carcinoma-in-situ to high-grade papillary urothelial carcinoma.

8 ee survival in platinum-refractory, advanced urothelial carcinoma.

9 adenectomy for patients with muscle-invasive urothelial carcinoma.

10 may inform the progression and treatment of urothelial carcinoma.

11 variably lost during progression to invasive urothelial carcinoma.

12 motherapy in locally advanced and metastatic urothelial carcinoma.

13 equired to improve survival of patients with urothelial carcinoma.

14 losely resembled that of the human low-grade urothelial carcinoma.

15 , biopsy of which showed invasive high-grade urothelial carcinoma.

16 patients with locally advanced or metastatic urothelial carcinoma.

17 treatment of unfit patients with metastatic urothelial carcinoma.

18 -line treatment for patients with metastatic urothelial carcinoma.

19 a useful therapeutic target in some cases of urothelial carcinoma.

20 ases were found in 15.8% of the animals with urothelial carcinoma.

21 equenced several diagnostic polypeptides for urothelial carcinoma.

22 cinoma of the urinary bladder and concurrent urothelial carcinoma.

23 fine the optimal regimen of chemotherapy for urothelial carcinoma.

24 days in patients with untreated, metastatic urothelial carcinoma.

25 erated regimen for the treatment of advanced urothelial carcinoma.

26 le-agent cisplatin in patients with advanced urothelial carcinoma.

27 l first-line treatment option for metastatic urothelial carcinoma.

28 FX) is an agent as yet unstudied in advanced urothelial carcinoma.

29 ly cisplatin-pretreated cohort with advanced urothelial carcinoma.

30 ting agents have modest activity in advanced urothelial carcinoma.

31 ological target and exploratory biomarker in urothelial carcinoma.

32 fered in activity between NIPUC and invasive urothelial carcinoma.

33 r), as a first-line treatment for metastatic urothelial carcinoma.

34 -based chemotherapy in first-line metastatic urothelial carcinoma.

35 can induce sustained responses in metastatic urothelial carcinoma.

36 on-free survival in patients with metastatic urothelial carcinoma.

37 administered to 125 patients with metastatic urothelial carcinoma.

38 rgets Nectin-4, which is highly expressed in urothelial carcinoma.

39 nocarcinoma, non-small-cell lung cancer, and urothelial carcinoma.

40 enocarcinoma, non-small-cell lung cancer, or urothelial carcinoma.

41 r patients with platinum-refractory advanced urothelial carcinoma.

42 patients with metastatic platinum-refractory urothelial carcinoma.

43 body, in patients with refractory metastatic urothelial carcinoma.

44 s with metastatic or surgically unresectable urothelial carcinoma.

45 n patients with platinum-refractory advanced urothelial carcinoma.

46 erapeutic treatment option for patients with urothelial carcinoma.

47 h platinum-refractory advanced or metastatic urothelial carcinoma.

48 per tract; 2 of them with additional bladder urothelial carcinomas.

49 interest in the role of Wnt/beta-catenin in urothelial carcinomas.

50 iptase (TERT) gene in 66% of muscle-invasive urothelial carcinomas.

51 atures for outcome prediction in stage Ta/T1 urothelial carcinomas.

52 nd survivin in patients with stage Ta and T1 urothelial carcinomas.

53 gene that suppresses growth of prostate and urothelial carcinomas.

54 mages are essential for helping detect small urothelial carcinomas.

55 GRE MR urography helped detect 74% of small urothelial carcinomas.

56 in 38% (17/47) of specimens with high-grade urothelial carcinomas.

57 or addition to other agents with activity in urothelial carcinomas.

58 ure can define MPBC-HGT1 within conventional urothelial carcinomas.

59 enign tissue and in specimens with low-grade urothelial carcinoma (0/23).

60 emonstrated CAMKV immunoreactivity), bladder urothelial carcinoma (1), and non-Hodgkin lymphoma (1).

61 adjuvant setting for patients with localized urothelial carcinoma(1,2), with one study reporting data

62 o a masked group containing 31 patients with urothelial carcinoma, 11 healthy individuals, and 138 pa

63 The incidence for bladder urothelial carcinoma, a common malignancy of the urinary

64 patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was re

65 We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene exp

66 n exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed with regions

67 patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-bas

68 mong patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free

69 rmed in three patients with BKPyV-associated urothelial carcinoma after renal transplantation.

70 terns from urine samples of 46 patients with urothelial carcinoma and 33 healthy volunteers.

71 is clonally enriched in chemotherapy-treated urothelial carcinoma and continues to shape the evolutio

72 oprotein, is associated with poor outcome in urothelial carcinoma and contributes to experimental tum

73 or therapeutic use of avelumab in metastatic urothelial carcinoma and it has received accelerated US

74 as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeti

75 ntext of bladder cancer, upper urinary tract urothelial carcinoma and renal cell carcinoma with focus

76 e from chemotherapy directs the evolution of urothelial carcinoma and shapes its clonal architecture

77 However, greater understanding of urothelial carcinoma and solid tumor biology has resulte

78 r the PI3K/AKT pathway in the development of urothelial carcinoma and suggested that inhibitors of th

79 role of COX-2 in the progression of bladder urothelial carcinoma and supporting its potential as a t

80 Despite a high prevalence of urothelial carcinoma and the risk of bladder carcinoma,

81 egregation, in 36% of papillary non-invasive urothelial carcinomas and 16% of invasive urothelial car

82 netic, and immune alterations in upper tract urothelial carcinomas and their role in shaping muscle i

83 d appetite and diarrhoea in one patient with urothelial carcinoma, and acute kidney injury [NSCLC], h

84 rs different tumor biology than that of pure urothelial carcinoma, and if this difference translates

85 xclusion criteria were obstructive uropathy, urothelial carcinoma, and metastatic cancer.

86 GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamou

87 phenotypes, including small cell carcinoma, urothelial carcinoma, and squamous cell carcinoma.

88 lycaemia [other solid tumours], retinopathy [urothelial carcinoma], and vomiting [urothelial carcinom

89 large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplati

90 morphological characteristics divergent from urothelial carcinoma are extreme examples of tumour hete

91 The majority of targeted agents studied in urothelial carcinoma are in the second-line setting; new

92 Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-

93 ons, infections, and cancers with a focus on urothelial carcinomas, are reported.

94 cribed in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic go

95 Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable, with 5-yea

96 Bladder urothelial carcinoma (BLC) is one of the most common can

97 he ICG pHLIP imaging agent marked high-grade urothelial carcinomas, both muscle invasive and nonmuscl

98 identified in various tumor types including urothelial carcinoma, but the ubiquitous presence of BKV

99 enhance chemotherapeutic response of bladder urothelial carcinomas by abrogating early tumour repopul

100 trated that FGFR1 expression is increased in urothelial carcinoma cell lines and tumors, which promot

101 we examined splice variants of FGFR1 in both urothelial carcinoma cell lines and tumors.

102 transformed human urothelial cells and many urothelial carcinoma cell lines exhibit constitutive HH

103 ceptor knockdown in UM-UC-3 and TCCSUP human urothelial carcinoma cell lines resulted in suppression

104 Knockdown of FGFR1 in urothelial carcinoma cell lines revealed differential FG

105 H1, the constitutive HH activity observed in urothelial carcinoma cell lines was HH ligand dependent.

106 the difference in intrinsic HH dependence of urothelial carcinoma cell lines, a gene expression signa

107 -immortalized normal human urothelial cells, urothelial carcinoma cell lines, and tumor samples and s

108 elial cells and from low-grade to high-grade urothelial carcinoma cell lines, whereas alternatively s

109 that inhibits normal bladder epithelial and urothelial carcinoma cell proliferation.

110 issues and promotes motility and invasion of urothelial carcinoma cells.

111 dependent signaling and motility of invasive urothelial carcinoma cells.

112 ociated antigen found on the surface of most urothelial carcinoma cells.

113 es that have been reported or are in ongoing urothelial carcinoma clinical trials, and highlight mole

114 ded in all four expansion cohorts (12 in the urothelial carcinoma cohort and one in each of the other

115 cer cohort, and three (13%, 2.7-32.4) in the urothelial carcinoma cohort.

116 ), non-small-cell lung cancer (cohort C), or urothelial carcinoma (cohort D), whose disease had progr

117 unresectable, locally advanced or metastatic urothelial carcinoma, conducted at 224 academic research

118 of the bladder (LELC-B) is a rare subtype of urothelial carcinoma consisting of undifferentiated epit

119 Many urothelial carcinomas contain activating point mutations

120 patients with MPBC-HGT1 and 64 conventional urothelial carcinomas (cUC) (reference set) was performe

121 ole of the IGF-IR in bladder cancer by using urothelial carcinoma-derived 5637 and T24 cells.

122 model for investigating sexual dimorphism in urothelial carcinoma development, and implicated synergy

123 RNA-overexpressing tumours [52 patients with urothelial carcinoma, eight patients with HNSCC, 20 pati

124 secutive adults with metastatic, progressive urothelial carcinoma enrolled in a National Cancer Insti

125 ther development for patients with localized urothelial carcinoma, especially cisplatin-ineligible pa

126 Correct identification of patients with urothelial carcinoma from those with other malignant and

127 sue microarrays with 693 non-muscle invasive urothelial carcinomas from Danish, Swedish, and Spanish

128 microarrays (TMAs) with a total of 859 Ta/T1 urothelial carcinomas from Danish, Swedish, Spanish, and

129 or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, we

130 ed on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomize

131 Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy.

132 Patients with metastatic urothelial carcinoma have a dismal prognosis and few tre

133 Multimodal paradigms for muscle-invasive urothelial carcinoma have demonstrated favorable clinica

134 Patients with metastatic urothelial carcinoma have few treatment options after fa

135 investigating changes in gene expression in urothelial carcinoma have generally compared tumors of d

136 Non-invasive methods for diagnosis of urothelial carcinoma have reduced specificity in patient

137 64, 95% confidence interval: 2.92, 7.38) and urothelial carcinoma (hazard ratio = 2.02, 95% confidenc

138 e for expansion to patients in four cohorts: urothelial carcinoma, head and neck squamous-cell cancer

139 le-agent cisplatin in patients with advanced urothelial carcinoma; however, durable progression-free

140 very early events in the natural history of urothelial carcinoma; (iii) chemotherapy-treated urothel

141 n of a highly specific biomarker pattern for urothelial carcinoma in a large group of patients with v

142 the tumor is the first line of treatment for urothelial carcinoma in situ (CIS), the precursor lesion

143 -cell clones also give rise to both SCCB and urothelial carcinoma in xenografts.

144 roximately 50% of the deadly muscle-invasive urothelial carcinomas in humans and urothelial carcinoma

145 opathy [urothelial carcinoma], and vomiting [urothelial carcinoma] in one patient each); no treatment

146 characterized papillary and flat noninvasive urothelial carcinomas, including 28 pTa low-grade transi

147 ureterectomy, disclosing residual high-grade urothelial carcinoma infiltrating the full thickness of

148 sy identified transitional cell carcinoma or urothelial carcinoma invading the muscularis propria of

149 Upper urinary tract urothelial carcinoma is a relatively uncommon disease an

150 Locally advanced or metastatic urothelial carcinoma is an incurable disease with limite

151 in-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response d

152 d several insights: (i) chemotherapy-treated urothelial carcinoma is characterized by intra-patient m

153 helial carcinoma; (iii) chemotherapy-treated urothelial carcinoma is enriched with clonal mutations i

154 understanding of the biology and genetics of urothelial carcinoma is helping to identify and define t

155 Urothelial carcinoma is now recognized as a disease of a

156 Development of targeted therapies for urothelial carcinoma is still in early stages, consequen

157 Urothelial carcinoma is the most common type of bladder

158 Urothelial carcinoma is the most common type of bladder

159 invasive urothelial carcinomas in humans and urothelial carcinoma is the most prevalent epithelial ca

160 eted delivery of cytotoxic drugs in invasive urothelial carcinoma (iUC), for which improved therapy i

161 patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without progression follow

162 sly untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

163 Urothelial carcinoma may be classified as either immune

164 A murine urothelial carcinoma (MB49) model expressing the male mi

165 or surgically unresectable locally advanced urothelial carcinoma, measurable disease (according to R

166 nrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare h

167 representing 1,445 patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell car

168 ab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU)

169 Metastatic urothelial carcinoma (mUC) has a very high mutational ra

170 unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/k

171 uscle-invasive bladder cancer and metastatic urothelial carcinoma (mUC), and as high as 80% in nonmus

172 icacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcin

173 enotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from plat

174 in-4-expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on >= 1 prior

175 3) occur in up to 80% of low-grade papillary urothelial carcinoma of the bladder (LGP-UCB) suggesting

176 p of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentati

177 owth factor receptor 3 (FGFR3) are common in urothelial carcinoma of the bladder (UC).

178 In urothelial carcinoma of the bladder (UCB), silencing of

179 cal management of human cancer, including in urothelial carcinoma of the bladder (UCB).

180 Urothelial carcinoma of the bladder accounts for approxi

181 By analyzing 56 ROIs from urothelial carcinoma of the bladder and upper tract urot

182 Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival a

183 Metastatic urothelial carcinoma of the bladder is generally incurab

184 expression to be associated with aggressive urothelial carcinoma of the bladder, as well as increase

185 Eligible patients had histologically proven urothelial carcinoma of the bladder, pT3-pT4 disease or

186 tment-naive advanced or recurrent metastatic urothelial carcinoma of the bladder, ureter, or urethra

187 cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.

188 both nonmuscle-invasive and muscle-invasive urothelial carcinoma of the bladder.

189 of multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

190 undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of the bladder.

191 newly diagnosed and histologically confirmed urothelial carcinoma of the bladder.

192 ized by a lower total mutational burden than urothelial carcinoma of the bladder.

193 Urothelial carcinoma of the renal pelvis is a deadly dis

194 we enrolled patients (age >/=18 years) with urothelial carcinoma of the renal pelvis, ureter, bladde

195 d by Aristolochia plants, is associated with urothelial carcinoma of the upper urinary tract (UUC).

196 mpound found in certain herbal medicines, in urothelial carcinomas of exposed populations.

197 Muscle-invasive urothelial carcinomas of the bladder (MIUCB) exhibit fre

198 ve urothelial carcinomas and 16% of invasive urothelial carcinomas of the bladder.

199 romise for the early detection of aggressive urothelial carcinomas of the bladder.

200 Eleven patients presented with urothelial carcinomas of the upper tract; 2 of them with

201 Urothelial carcinomas of the upper urinary tract (UTUCs)

202 s associated with chronic kidney disease and urothelial carcinomas of the upper urinary tract.

203 , with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder.

204 a strong association with transitional cell (urothelial) carcinoma of the upper urinary tract.

205 Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and inte

206 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histolo

207 e an opportunity to improve the treatment of urothelial carcinoma outside the bladder.

208 ns of epidermal growth factor (EGF) and most urothelial carcinomas overexpress EGF receptor (EGFr), r

209 patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3).

210 tin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluate

211 Advanced urothelial carcinoma patients were screened for Her-2/ne

212 y characterized Her-2/neu status in advanced urothelial carcinoma patients.

213 ponse to PD-L1 blockade in a large cohort of urothelial carcinoma patients.

214 ic value of the protein expressions in Ta/T1 urothelial carcinomas patients.

215 We identified a diagnostic urothelial-carcinoma pattern of 22 polypeptide masses.

216 multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based ch

217 patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and

218 es of combined hazard ratio (HR) for bladder urothelial carcinoma recurrence, cancer-specific surviva

219 ), respectively; and for upper urinary tract urothelial carcinoma recurrence, CSS and OS were 2.27 (9

220 in urothelium by SV40 T antigen resulted in urothelial carcinoma, resembling human high-grade carcin

221 ial carcinoma of the bladder and upper tract urothelial carcinoma, ROICellTrack identified distinct c

222 Immunohistochemical analysis of urothelial carcinoma samples found loss of PTEN protein

223 SCCB model and a cohort of patient SCCB and urothelial carcinoma samples to characterize molecular s

224 Cystitis and invasive high-grade urothelial carcinoma samples were analyzed.

225 xome sequencing and clonality analysis of 72 urothelial carcinoma samples, including 16 matched sets

226 istry in a small cohort, including low-grade urothelial carcinoma samples.

227 peptides correctly classified all samples of urothelial carcinoma (sensitivity 100% [95% CI 87-100) a

228 dentified in conventional and micropapillary urothelial carcinoma, small cell, and squamous cell carc

229 ultimately identified to have 23 upper-tract urothelial carcinomas smaller than 2 cm or carcinoma in

230 as, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the t

231 ontinuation were reported than in metastatic urothelial carcinoma studies.

232 between small-cell carcinoma and coexisting urothelial carcinoma suggest that both tumor components

233 lly confirmed locally advanced or metastatic urothelial carcinoma that had progressed after at least

234 treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-

235 d carcinogen exposure and developed invasive urothelial carcinomas that strongly resembled the human

236 or those with non-small-cell lung cancer and urothelial carcinoma) that included platinum (for all tu

237 noma and continues to shape the evolution of urothelial carcinoma throughout its lifetime.

238 Significantly, in urothelial carcinoma tissues there was increased Pyk2 lo

239 (TCR) clonality inform clinical outcomes in urothelial carcinoma treated with atezolizumab.

240 encouraging number of patients with advanced urothelial carcinoma treated with this regimen experienc

241 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment.

242 In the first-line treatment of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte an

243 n in renal clear cell carcinomas and bladder urothelial carcinomas, tumors associated with TSC gene m

244 f 27 patients), and colitis in patients with urothelial carcinoma (two [8%] of 24 patients).

245 the BK virus (BKV) in the carcinogenesis of urothelial carcinoma (UC) after renal transplantation ar

246 variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable thera

247 Current diagnostic methods for canine urothelial carcinoma (UC) are technically challenging or

248 enal cell carcinoma (RCC) and 3-fold risk of urothelial carcinoma (UC) compared with the general popu

249 ninvasive urine test has become the goal for urothelial carcinoma (UC) diagnosis and surveillance.

250 tibility complex (MHC) class I expression in urothelial carcinoma (UC) have not been previously repor

251 ecognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients

252 Urothelial carcinoma (UC) is a common disease causing si

253 fect of pre-operative renal insufficiency on urothelial carcinoma (UC) prognosis has been investigate

254 tivating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available o

255 treatment options for progressive metastatic urothelial carcinoma (UC).

256 eatment of patients with upper urinary tract urothelial carcinoma (UC).

257 advanced or metastatic cisplatin-ineligible urothelial carcinoma (UC).

258 ly predict clinical outcome in patients with urothelial carcinoma (UC).

259 er therapy across many indications including urothelial carcinoma (UC).

260 ll renal cell carcinoma (ccRCC; n = 51), and urothelial carcinoma (UC; n = 227) TBP were included.

261 ous cell carcinomas (SCC, OR = 4.90) than in urothelial carcinomas (UC, OR = 3.62).

262 in many cancer models, although its role in urothelial carcinoma (UCC) has not been extensively expl

263 The study utilized a series of urothelial carcinomas (UCs) by tissue microarray, on whi

264 Like many carcinomas, urothelial carcinoma (UroCa) is associated with chronic

265 ment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated f

266 Upper tract urothelial carcinoma (UTUC) is characterized by a distin

267 suggested an overlap of CDC with upper tract urothelial carcinoma (UTUC), making the pathological dia

268 cal nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-

269 excision (RNU) for patients with upper tract urothelial carcinoma (UTUC).

270 cal nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).

271 that TGIF contributes to the progression of urothelial carcinoma via the phosphatidylinositol 3-kina

272 polypeptide from the diagnostic pattern for urothelial carcinoma was identified as fibrinopeptide A-

273 Urothelial carcinoma was the most common malignancy afte

274 ndent cohort of 94 ICB-treated patients with urothelial carcinoma was used for validation where LAG(+

275 confirm the role of the PI3K/AKT pathway in urothelial carcinoma, we generated mice containing biall

276 April 24, 2015, 86 patients with metastatic urothelial carcinoma were enrolled in the nivolumab mono

277 -hundred fifty-five assessable patients with urothelial carcinoma were randomized to receive either s

278 2016, 329 patients with advanced metastatic urothelial carcinoma were screened for enrolment into th

279 Fifty-two patients with advanced urothelial carcinoma were treated on one day with paclit

280 Ambulatory patients with advanced urothelial carcinoma were treated with IFX 3,750 mg/m2 a

281 affin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific a

282 In addition, basal carcinomas and prostatic urothelial carcinomas were observed.

283 ll cell lung cancer, 3 in melanoma, and 3 in urothelial carcinoma) were selected for the meta-analysi

284 atients with previously untreated metastatic urothelial carcinoma who benefit from treatment with imm

285 Patients (aged >/=18 years) with metastatic urothelial carcinoma who had progressed after platinum-b

286 rial in patients with advanced or metastatic urothelial carcinoma who progressed during or after plat

287 tcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, p

288 patients with locally advanced or metastatic urothelial carcinoma who were previously treated with pl

289 patients with locally advanced or metastatic urothelial carcinoma who were previously treated with pl

290 patients with locally advanced or metastatic urothelial carcinoma who were previously treated with pl

291 th inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after

292 patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after prev

293 s with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurre

294 e next generation of clinical management for urothelial carcinoma will witness the use of multimarker

295 y pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone me

296 Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined

297 Pathology revealed pathologic extravesical urothelial carcinoma, with disease in one of 25 lymph no

298 These mice developed typical renal pelvic urothelial carcinomas, with an incidence of 57.1% in mic

299 ded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymph

300 December 2014, 506 patients with metastatic urothelial carcinoma without prior chemotherapy for meta